Interview with Jacek Barlinski, Country Manager, Nycomed Poland
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
Address:
Tel:
Nycomed is a privately owned, global pharmaceutical company with headquarters in Zurich, Switzerland. The company employs 12,000 associates worldwide and has affiliates in more than 50 countries.
Nycomed has a strong presence in Europe and in the emerging markets in Russia/Commonwealth of Independent States, Asia and Latin America.
Business results and main therapeutic areas
In 2009, total sales reached € 3.2 billion, with an adjusted EBITDA of € 1.1 billion. Nycomed ranks 28th among global pharmaceutical companies and is the 16th largest provider of OTC medicines.
Nycomed’s differentiated portfolio of branded medicines is focused on gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. An extensive range of OTC products completes the portfolio.
Global R&D and Manufacturing presence
Research and Development is conducted at three sites in Europe and one in India. New products are sourced from our own internal Discovery organisation and in-licensed from external companies such as small biotechs. Establishing long-term partnerships is a cornerstone of Nycomed´s growth strategy.
Nycomed has 16 manufacturing sites: 5 centres of competence in Europe for global products as well as 11 production sites for regional products in fast-growing countries such as Brazil and Mexico. A major investment is being made in a new pharmaceutical plant in Russia, currently Nycomed’s biggest single market.
Nycomed provides branded medicines for hospitals, specialists and general practitioners, as well as over-the-counter (OTC) medicines. Our strong global brands complement product portfolios adapted to local preferences. Around the world, our guiding principle is to develop “medicines that matter”
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
Philippe Coudiere, general manager of Pierre Fabre Dermo-cosmetics Poland, highlights the key partnerships the company has nurtured with pharmacists and dermatologists and the importance of clinical data for their products.…
Artur Chabowski, president of Mabion, a pioneer Polish biotech player, discusses the historic partnership of their product, MabionCD20 with Mylan for the EU and Baltic states and the opportunities this…
Markus Sieger, CEO of Polpharma, outlines his global strategy for the company, focused on OTC and CHC, internationalization and a strong R&D strategy to push forward biosimilars. Furthermore, he highlights…
Mariusz Ignatowicz, PwC healthcare sector leader for CEE, discusses the funding of the Polish healthcare ecosystem and the need to find an alternative payer in the long-term Additionally, he highlights…
Colm Murphy, general plant manager of Anpharm, a key European production site for the Servier group, highlights major investments in recent years, such as the state-of-the-art QC Lab, and his…
Krzysztof Kołodziejski, country manager of Santen Poland, discusses the strategy he put in place to modernize the business culture of the affiliate and how this has led to great success.…
Jarosław Król, president of Polfa Tarchomin, highlights the strategic moves he has made to stabilise the company and the need to deliver a new, fresh portfolio to drive forward profit.…
Andrzej Tarnkowski, founder and owner of Antar, a Polish success story within the orthopaedic field, discusses the company’s successful international expansion into various markets, including Germany, while highlighting the opening…
Joanna Drewla, general manager of Servier Poland, discusses Polish healthcare challenges and looks at areas for improvement to create a sustainable balance for market access of innovative treatments. Furthermore, she…
Stefan Jaworski-Martycz, country manager Poland and CEE Cluster Lead of Théa, a leading French ophthalmology company, discusses the intricacies of the Polish ophthalmology environment and the key steps for the…
Dorota Hryniewiecka-Firlej, president of Pfizer Poland, discusses the current state of the Polish innovation landscape and importance of a tight-knit relationship between the innovative pharmaceutical market and the government for…
Robert Bitner, country manager of Galderma Poland, give his first impressions of the Polish dermatology landscape and how his past experiences have prepared him for the challenges ahead. Additionally, he…
See our Cookie Privacy Policy Here
